SAB Biotherapeutics, Inc. Announces First Publication of Promising Nonclinical Data for Sab-183 Against Pneumonic Plague in the Journal Antibodies
May 12, 2023 at 06:00 pm IST
Share
SAB Biotherapeutics, Inc. announced the publication of nonclinical data in the medical journal Antibodies. The data are from a study
conducted in collaboration with the United States Army Medical Research Institute of Infectious Diseases (USAMRID) highlighting that fully-human immunoglobulins derived from Tc bovines can protect mice from Yersinia pestis, a Tier 1 select bacterial biothreat agent that can rapidly cause fatal infections and is associated with pneumonic plague as well as bubonic plague. SAB-183, the Tc bovine derived fully-human immunoglobulin, demonstrated increased opsonization and phagocytosis of Y. pestis in vitro and elicited a strong immune response with significant protection to mice exposed to Y. pestis in vivo. Y. pestis is a major biothreat due to its capacity for aerosol dissemination and its highly contagious nature in the pneumonic form. Furthermore, as the study notes, drug-resistant isolates of Y. pestis are on the rise and constitute a significant concern for the public health and biodefense communities. In lieu of any approved vaccine for this pathogen, effective antibody therapies and other countermeasures are needed to ensure preparedness. This study confirmed that rapid production of antibodies from Tc bovines provides broad protection against plague and other bacterial or viral infections and can be used to produce treatments to counter the challenges of antibiotic resistance and rapid mutation of pathogens. In contrast to monoclonal antibodies, polyclonal antibodies derived from Tc
bovines afford greater epitope coverage, which may mitigate loss of efficacy against a mutating pathogen and emergence of escape mutants.
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing fully human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company's lead asset, SAB-142, targets type 1 diabetes (T1D) with a disease-modifying therapeutic approach. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine, the only transgenic animal with a human artificial chromosome, its DiversitAb drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, fully-human IgGs that can address a wide range of serious unmet needs in human diseases. The Company's SAB-176 pipeline program is a multivalent, broadly neutralizing -human polyclonal IgG therapeutic candidate in development for the treatment or prevention of severe influenza.